Observations placeholder

The drug aprotinin (Trasylol, ), is the small protein bovine pancreatic trypsin inhibitor (BPTI), an antifibrinolytic molecule that inhibits trypsin and related proteolytic enzymes.

Under the trade name Trasylol, aprotinin was used as a medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery.

Its main effect is the slowing down of fibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use was to decrease the need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss. The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death; this was confirmed by follow-up studies.

Trasylol sales were suspended in May 2008, except for very restricted research use. In February 2012 the European Medicines Agency (EMA) scientific committee reverted its previous standpoint regarding aprotinin, and has recommended that the suspension be lifted.

On Feb, 13, 2016: 9,352 people reported to have side effects when taking Trasylol. Among them, 1 people (0.01%) has Hallucination.

Time on Trasylol when people have Hallucination  :

On Feb, 10, 2016: 9,352 people reported to have side effects when taking Trasylol. Among them, 4,519 people (48.32%) have Death.

Time on Trasylol when people have Death  :

Gender of people who have Death when taking Trasylol  :

Age of people who have Death when taking Trasylol  :

Top conditions involved for these people :

1. Hypertension (161 people, 3.56%)